Valuation : Sprint Bioscience AB

Market Cap 343M 35.85M 30.83M 29.02M 26.49M 49.53M 3.39B 49.76M 133M 1.73B 135M 132M 5.63B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 343M 35.85M 30.83M 29.02M 26.49M 49.53M 3.39B 49.76M 133M 1.73B 135M 132M 5.63B EV / Sales 2026 *
3.95x
EV / Sales 2027 * 3.54x
Free-Float
72.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week+2.20%
Current month+1.56%
1 month-6.61%
3 months-5.25%
6 months+71.50%
Current year+121.09%
1 week 3.1
Extreme 3.1
3.38
1 month 2.77
Extreme 2.77
3.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.51
Extreme 0.512
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
5.4
10 years 0.36
Extreme 0.36
41.5
Manager TitleAgeSince
Chief Executive Officer 42 2023-09-30
Chief Tech/Sci/R&D Officer 55 2008-12-31
Director of Finance/CFO 55 2026-05-03
Director TitleAgeSince
Chairman 70 2009-12-31
Director/Board Member 50 2018-12-31
Chairman 58 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%+2.20%+432.79%+8.70% 35.84M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.36%+0.45%+81.71%+160.70% 27.91B
Weighted average by Cap. -1.52%+0.18%+38.42%+137.33%

Financials

2026 *2027 *
Net sales 86.8M 9.08M 7.8M 7.35M 6.71M 12.54M 857M 12.59M 33.62M 439M 34.08M 33.33M 1.42B 96.8M 10.12M 8.7M 8.19M 7.48M 13.98M 956M 14.05M 37.49M 489M 38M 37.17M 1.59B
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
26-09-04 SEK 3.250 -1.22% 173,438
26-09-03 SEK 3.290 +0.30% 110,005
26-09-02 SEK 3.280 -0.61% 312,923
26-09-01 SEK 3.300 +3.12% 268,442
26-08-31 SEK 3.200 +0.63% 178,120

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock